HC Wainwright maintains $30 target on Olema Pharma stock

Published 19/03/2025, 12:32
HC Wainwright maintains $30 target on Olema Pharma stock

Wednesday, H.C. Wainwright reiterated a Buy rating and a $30.00 price target on Olema Pharmaceuticals (NASDAQ:OLMA) stock, representing over 600% upside from the current price of $4.14. According to InvestingPro data, the stock is trading near its 52-week low of $3.95, having declined about 69% over the past six months. The broader analyst consensus remains highly bullish with a 1.38 rating (where 1 is Strong Buy). The firm’s analyst emphasized the promising results from Olema’s Phase 2 study of palazestrant (pala) in combination with ribociclib (ribo) for treating ER+/HER2- metastatic breast cancer (mBC). The study showed a median progression-free survival (PFS) of 13.8 months for all patients and 13.1 months for those previously treated with CDK4/6 inhibitors and endocrine therapy (ET).

The analyst noted the median PFS of over 13 months for both patient groups in Olema’s study could be considered potentially best-in-class when compared to similar oral SERD + CDK4/6i combination studies. Competitor studies have reported median PFS ranging from 8-9 months. The current data, with 24 patients still on study as of February 18, 2025, suggests the potential for this number to increase, with more mature data expected to be presented later in the year, possibly at the American Society of Clinical Oncology (ASCO) meeting.

Olema’s reported data also indicates a potentially differentiated efficacy profile for palazestrant and ribociclib across various patient subtypes, including those with ESR1 mutant (ESR1m) and ESR1 wild-type (ESR1wt). This distinction is seen as a positive indicator for Olema’s planned Phase 3 (OPERA-02) trial in 2025, which aims to explore the combination as a first-line (1L) treatment.

The analyst’s reiteration of the Buy rating and the $30 price target comes after Olema Pharmaceuticals disclosed its fourth-quarter and full-year financial results for 2024. The results included updates on the company’s clinical developments and progress in its ongoing trials. InvestingPro analysis reveals the company maintains a strong liquidity position with a current ratio of 10.4, though it’s currently experiencing rapid cash burn. InvestingPro subscribers have access to 11 additional key insights about OLMA’s financial health and market position.

Olema Pharmaceuticals is focused on the development of targeted therapies for women’s cancers, and the latest results from its Phase 2 trial have been met with optimism by H.C. Wainwright. The firm’s positive outlook on the stock remains unchanged following the recent data announcement. With a market capitalization of $308 million and trading below book value at a P/B ratio of 0.75, InvestingPro analysis suggests the stock may be undervalued at current levels, despite near-term profitability challenges. Discover more detailed valuation metrics and financial health indicators with an InvestingPro subscription.

In other recent news, Olema Pharmaceuticals announced significant developments in its ongoing clinical trials and corporate activities. The company reported promising results from its Phase 2 study of palazestrant combined with ribociclib for treating ER+/HER2- metastatic breast cancer. The study showed a median progression-free survival (PFS) of 13.8 months, surpassing the typical 8-9 month range observed in similar studies. Olema plans to initiate a Phase 3 trial in 2025 and anticipates presenting updated data at a medical conference later this year. H.C. Wainwright reaffirmed its Buy rating and $30 price target for Olema, reflecting confidence in the drug’s efficacy.

Additionally, Olema Pharmaceuticals disclosed an unregistered exchange of equity securities with Bain Capital Life Sciences Opportunities IV, L.P., Paradigm BioCapital International Fund Ltd., and BVF Partners L.P. The transaction involves exchanging 6,070,000 shares of common stock for pre-funded warrants. These warrants have an exercise price of $0.0001 per share and are immediately exercisable. This exchange is conducted under Section 3(a)(9) of the Securities Act, allowing for the exchange of securities without registration. The closing of the transaction is expected on January 13, 2025, with the estimated outstanding shares of common stock post-exchange being 68,333,065.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.